Stockscreener 앱 받기
109.35
1.90%
2.04
전일 마감가:
$107.31
열려 있는:
$108.62
하루 거래량:
2.26M
Relative Volume:
1.48
시가총액:
$215.98B
수익:
$51.72B
순이익/손실:
$11.94B
주가수익비율:
18.60
EPS:
5.88
순현금흐름:
$13.81B
1주 성능:
+3.72%
1개월 성능:
+9.65%
6개월 성능:
-7.02%
1년 성능:
+6.62%
1일 변동 폭
$108.08
$109.78
1주일 범위
$106.10
$109.78
52주 변동 폭
$92.35
$120.92
노바티스 ADR Stock (NVS) Company Profile
NVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
109.35 | 215.98B | 51.72B | 11.94B | 13.81B | 5.88 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
노바티스 ADR Stock (NVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-02-12 | 개시 | Morgan Stanley | Underweight |
| 2025-02-04 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-12-04 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-09-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-09-05 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-09-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-19 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-02-23 | 개시 | BMO Capital Markets | Market Perform |
| 2024-01-23 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 재개 | UBS | Buy |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-09-25 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-03-27 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2023-01-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-12-05 | 업그레이드 | Stifel | Hold → Buy |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-05-09 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 재개 | Citigroup | Buy |
| 2021-12-14 | 다운그레이드 | Redburn | Buy → Neutral |
| 2021-12-06 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 개시 | Bernstein | Mkt Perform |
| 2021-03-10 | 다운그레이드 | Argus | Buy → Hold |
| 2021-02-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2020-09-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-03-10 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-04-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-04-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-10 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 재개 | Jefferies | Buy |
| 2018-10-09 | 개시 | Guggenheim | Neutral |
| 2018-09-10 | 업그레이드 | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2018-05-25 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 재확인 | Leerink Partners | Outperform |
| 2017-12-06 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 개시 | Liberum | Buy |
모두보기
노바티스 ADR 주식(NVS)의 최신 뉴스
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
NVS Quantitative Stock Analysis - Nasdaq
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novartis to buy Anthos Therapeutics in $3.1bn deal - Proactive Investors USA
Novartis 2017 Financial Results - Novartis
ATI Inc [ATI] Records 200-Day SMA of $59.51 - Knox Daily
Taking a look at what insiders are doing to gauge the America Movil S.A.B.DE C.V. ADR (AMX)’s direction - Knox Daily
Novartis AG ADR [NVS] Officer makes an insider purchase of 6,566 shares worth 0.73 million. - Knox Daily
NVS’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Novartis AG ADR (NVS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Novartis AG ADR [NVS] is 12.85% higher this YTD. Is it still time to buy? - The DBT News
Delhi High Court grants ad interim injunction to leading pharmaceutical company NOVARTIS; restrains use of NOVITAS mark - SCC Online
HSBC Securities downgrades Novartis AG ADR (NVS) rating to a Reduce - Knox Daily
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond - sharewise
Novartis's SWOT analysis: pharma giant's stock navigates generic headwinds - Investing.com
Novartis Earnings: Results In-Line; Growth Brands to Offset Entresto Loss of Exclusivity in 2025 - Morningstar
Novartis Financial Results – Q2 2023 - Novartis
World Economic Forum Annual Meeting 2025 - Novartis
Novartis Posts Q4 Earnings And Sales Beat, Shares Gain - Barchart
Novartis 2022 Financial Results - Novartis
Novartis at ASH - Novartis
Novartis 2021 Financial Results - Novartis
Novartis Financial Results – Q1 2023 - Novartis
Novartis ADR earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
J.P. Morgan Healthcare Conference 2024 - Novartis
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain - Nasdaq
Novartis 2023 Financial Results - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Building belonging - Novartis
Novartis in Society Integrated Report 2024 - Novartis
Novartis to Report Q4 Earnings: What's in the Offing? - Yahoo Finance
AI Pharma: 2 Paths to AI-Powered Drug Investment - sharewise
Inari Medical Inc (NASDAQ: NARI): Getting A Free Pass? - Stocks Register
Metrics That Matter About Deutsche Bank AG (NYSE: DB) - Stocks Register
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Japan Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Canada Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
노바티스 ADR (NVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.08%
0.07%
자본화:
|
볼륨(24시간):